{"id":"W4310120142","doi":"10.1182/blood-2022-157691","title":"Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada); Princess Margaret Cancer Centre; Jewish General Hospital; McGill University; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Follicular lymphoma; Medicine; Refractory (planetary science); Safety profile; Oncology; Internal medicine; Rituximab; Lymphoma; Phases of clinical research; Follicular phase; Clinical trial; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000669276,0.0005357335,0.0009031229,0.0003838385,0.0006345869,0.00007659404,0.0004279413,0.0001194872,0.002221106],"category_scores_gemma":[0.00005320195,0.0004144172,0.0001164719,0.001397552,0.000143946,0.0002402903,0.0001667942,0.0006513908,0.00001306665],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004538578,"about_ca_system_score_gemma":0.0005727221,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001783055,"about_ca_topic_score_gemma":0.0002947648,"domain_scores_codex":[0.9952576,0.0005702003,0.0007784247,0.001175827,0.001413666,0.0008042759],"domain_scores_gemma":[0.9977543,0.0002228858,0.0003220497,0.001241436,0.0002091465,0.0002501709],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4816989,0.1870698,0.2132428,0.00007605745,0.007877487,0.002923012,0.02992667,0.0006223822,0.02441814,0.000007279891,0.001115529,0.05102197],"study_design_scores_gemma":[0.5884919,0.06744541,0.3231099,0.0002878327,0.0005698654,0.00004013249,0.005796387,0.0006697365,0.004939782,0.0000153334,0.007660824,0.0009729739],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9908718,0.00038409,0.00000679511,0.0002086429,0.00004594955,0.00638752,0.0004770185,0.0001814688,0.001436747],"genre_scores_gemma":[0.991339,0.00007802617,0.0006350488,0.0001236222,0.00005452605,0.0006291188,0.00113748,0.000171577,0.005831591],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1196244,"threshold_uncertainty_score":0.9998308,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01069748530457965,"score_gpt":0.2509131653512022,"score_spread":0.2402156800466226,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}